XR-17 encapsulates APIs in micelles, making them water-soluble and suitable for intravenous injection.

Vivesto’s toxicological and clinical studies indicate several key benefits of XR-17:

  • Improved delivery of intravenously administered drugs, intended to avoid mandatory use of corticosteroid before intravenous administration
  • Shorter intravenous infusion times than with some solvent-based versions of the drugs, making treatment more convenient for patients and healthcare providers
  • Favorable API to solvent ratio, intended to keep solvent portion of the drug low while maximizing the API delivery
  • Free from alcohol and proteins of human or animal origin